Skip to content

Recursos

Centros de Tratamiento de Hemofilia

Muchas personas con trastornos hemorrágicos utilizan los recursos de su centro de tratamiento de la hemofilia (HTC, por sus siglas en inglés). Las personas que acuden a centros de tratamiento de la hemofilia no sólo encontrarán lo más novedoso en atención médica, sino que también se beneficiarán de un personal con experiencia y atento que se toma el tiempo necesario para desarrollar planes integrales de atención terapéutica para los pacientes y sus familias.

Centros de Tratamiento de Hemofilia Locales:

  • Gulf States Hemophilia & Thrombophilia Center
    6655 Travis, Suite 100
    Houston, TX 77030
    Phone: 713-500-8360
  • Texas Children’s Hemophilia & Thrombosis Center
    6701 Fannin Street
    Suite 1580
    Houston, Texas 77030
    Phone: 832-822-4362
  • Children’s Blood and Cancer Center of Central Texas – Dell Children’s Specialty Pavillion
    4910 Mueller Blvd Ste 200
    Austin, TX 78723
    Phone: 512-628-1900
  • South Texas Hemophilia Treatment Center
    Gateway Medical Park
  • 8435 Wurzbach Road
    San Antonio, TX 78229
    Phone: 210-567-7000

Programas de Asistencia

El trabajador social de su Centro de Tratamiento de Hemofilia puede ayudarle a buscar recursos de asistencia financiera.

Póngase en contacto con su trabajador social para obtener una solicitud de remisión de LSBDF Helping Hands.

Programa de asistencia para la hemofilila

Sitio web

Programa de asistencia para la hemofilila

Programa de asistencia de hemofilia ayuda a los tejanos con hemofilia a cubrir sus facturas médicas. Se proporciona asistencia con productos de sustitución del factor sanguíneo o reembolso del pago de prima del seguro médico.

¿Quién es eligible para los servicios?

HAP está disponible para cualquier persona que:

  • Vive en Texas
  • Es mayor de 18 años
  • Tiene un ingreso igual o inferior al 200 por ciento de las Directrices Federales de Pobreza
  • Tiene un diagnóstico de la hemofilia de un médico con licencia
  • No está encarcelado o bajo la tutela del estado
  • No es eligible para el Programa de Niños con Necesidades Especiales de Servicios de Salud, Medicaid o Medicare.

La Fundación PAN

https://www.panfoundation.org

News from HFA

  • Leading Advocacy Organizations Celebrate Federal Rule Strengthening Protections Against Disability Discrimination 

    The Bleeding Disorders Substance Use and Mental Health Access Coalition (BD SUMHAC), National Bleeding Disorder Foundation (NBDF) and Hemophilia Federation of America (HFA) are pleased to share that after advocacy from the bleeding disorders community, the U.S. Department of Health and Human Services (HHS), through its Office for Civil Rights (OCR), finalized a new rule The post Leading Advocacy Organizations Celebrate Federal Rule Strengthening Protections Against Disability Discrimination  appeared first on Hemophilia Federation of America.

  • Advocacy News: April 2024

    Word from Washington After one year, Medicaid coverage losses during “unwinding” continue to surpass worst fears According to the latest KFF Medicaid Unwinding Enrollment Tracker, more than 21 millionAmericans have lost Medicaid coverage during the first year after states were allowed to resume eligibility verifications following the COVID-19 public health emergency. There remains wide variation The post Advocacy News: April 2024 appeared first on Hemophilia Federation of America.

  • May is Hepatitis Awareness Month

    In 2001, the Centers for Disease Control and Prevention designated the month of May as Hepatitis Awareness Month to bring awareness and attention to those living with viral hepatitis. In the 1980s and ’90s, thousands of people with hemophilia contracted HIV and hepatitis C (HCV) from the contaminated blood supply transmitted by clotting factor products. The post May is Hepatitis Awareness Month appeared first on Hemophilia Federation of America.

  • FDA Approves One-Time Gene Therapy for Adults with Hemophilia B

    From Pfizer: Pfizer Inc. announced that the US Food and Drug Administration has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing The post FDA Approves One-Time Gene Therapy for Adults with Hemophilia B appeared first on Hemophilia Federation of America.

  • Advocacy News: March 2024

    Word From Washington Federal Agencies Supreme Court Congress State of the States Oregon becomes first state in 2024 to pass protections against copay accumulator adjusters. Oregon Governor Tina Kotek (D) signed legislation unanimously passed by the House and Senate that protects consumers in state-regulated health plans from harmful and discriminatory copay accumulator adjuster programs (CAAPs). The post Advocacy News: March 2024 appeared first on Hemophilia Federation of America.